Products
No drugs containing gatifloxacin are registered in many countries. Eye drops are available in the United States. Tablets and solutions for injection are no longer available because of glucose metabolism disorders (dysglycemia: hypoglycemia, hyperglycemia) that occurred with systemic administration. Gatifloxacin was first approved in 1999.
Structure and properties
Gatifloxacin (C19H22FN3O4, Mr = 375.4 g/mol) is an 8-methoxyfluoroquinolone with a 3-methylpiperazine group at C7.
Effects
Gatifloxacin (ATC J01MA16) has antibacterial properties. The effects are due to inhibition of bacterial DNA gyrase and topoisomerase IV. These enzymes are involved in DNA replication, transcription, and DNA repair.
Indications
For the treatment of bacterial conjunctivitis with susceptible pathogens.
Dosage
According to the SmPC. The drops are usually given into the eyes two to four times daily. More frequent administration is also possible on the 1st day of treatment. See also under Administering eye drops.
Contraindications
Gatifloxacin is contraindicated in the presence of hypersensitivity. For complete precautions, see the drug label.
Adverse Effects
Possible adverse effects include worsening conjunctivitis, eye irritation, taste disturbance, and eye pain.
